Serge Belanger
Stock Analyst at Needham
(3.79)
# 768
Out of 4,749 analysts
318
Total ratings
49.49%
Success rate
8.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Serge Belanger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Reiterates: Buy | $22 | $13.97 | +57.48% | 12 | Jan 21, 2025 | |
| RVNC Revance Therapeutics | Reiterates: Hold | n/a | $3.63 | - | 21 | Jan 17, 2025 | |
| OMER Omeros | Reiterates: Hold | n/a | $8.62 | - | 5 | Jan 17, 2025 | |
| PCRX Pacira BioSciences | Maintains: Buy | $22 → $30 | $26.33 | +13.94% | 25 | Jan 13, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Buy | $14 → $15 | $7.90 | +89.87% | 11 | Jan 13, 2025 | |
| COLL Collegium Pharmaceutical | Upgrades: Buy | $46 | $32.12 | +43.21% | 24 | Jan 10, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $19 | $14.23 | +33.52% | 26 | Jan 9, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $38 | $19.38 | +96.08% | 15 | Jan 7, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Hold | n/a | $0.65 | - | 16 | Dec 20, 2024 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $18 → $20 | $13.24 | +51.06% | 17 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.79 | +235.20% | 17 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.94 | +103.05% | 17 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $8.91 | +214.25% | 17 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $22.29 | +61.51% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $4 | $1.70 | +135.29% | 20 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $72 | $49.46 | +45.57% | 19 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.93 | +545.16% | 11 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $39.98 | +50.08% | 11 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $18 | $10.27 | +75.27% | 14 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $62 | $45.99 | +34.81% | 10 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $34.87 | - | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.24 | - | 1 | Mar 31, 2022 |
Evolus
Jan 21, 2025
Reiterates: Buy
Price Target: $22
Current: $13.97
Upside: +57.48%
Revance Therapeutics
Jan 17, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.63
Upside: -
Omeros
Jan 17, 2025
Reiterates: Hold
Price Target: n/a
Current: $8.62
Upside: -
Pacira BioSciences
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $30
Current: $26.33
Upside: +13.94%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $14 → $15
Current: $7.90
Upside: +89.87%
Collegium Pharmaceutical
Jan 10, 2025
Upgrades: Buy
Price Target: $46
Current: $32.12
Upside: +43.21%
Liquidia
Jan 9, 2025
Reiterates: Buy
Price Target: $19
Current: $14.23
Upside: +33.52%
Viridian Therapeutics
Jan 7, 2025
Reiterates: Buy
Price Target: $38
Current: $19.38
Upside: +96.08%
Verrica Pharmaceuticals
Dec 20, 2024
Reiterates: Hold
Price Target: n/a
Current: $0.65
Upside: -
Arcutis Biotherapeutics
Dec 17, 2024
Maintains: Buy
Price Target: $18 → $20
Current: $13.24
Upside: +51.06%
Dec 13, 2024
Reiterates: Buy
Price Target: $6
Current: $1.79
Upside: +235.20%
Dec 12, 2024
Reiterates: Buy
Price Target: $8
Current: $3.94
Upside: +103.05%
Dec 5, 2024
Reiterates: Buy
Price Target: $28
Current: $8.91
Upside: +214.25%
Dec 5, 2024
Reiterates: Buy
Price Target: $36
Current: $22.29
Upside: +61.51%
Dec 4, 2024
Reiterates: Buy
Price Target: $4
Current: $1.70
Upside: +135.29%
Dec 2, 2024
Reiterates: Buy
Price Target: $72
Current: $49.46
Upside: +45.57%
Nov 13, 2024
Reiterates: Buy
Price Target: $6
Current: $0.93
Upside: +545.16%
Nov 13, 2024
Reiterates: Buy
Price Target: $60
Current: $39.98
Upside: +50.08%
Oct 31, 2024
Maintains: Buy
Price Target: $10 → $18
Current: $10.27
Upside: +75.27%
Sep 12, 2024
Reiterates: Buy
Price Target: $62
Current: $45.99
Upside: +34.81%
Aug 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $34.87
Upside: -
Mar 31, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.24
Upside: -